FLT3 and myeloproliferative neoplasm: JAK2V617F is the most common event in MPN-BP but is not observed in de novo AML (7, 53), whereas mutations in FLT3, NPM1, DNMT3A, which are most common events in de novo AML, are rarely observed in MPN-BP (7).